Teladoc Health (NYSE:TDOC) Faces Challenges Amidst Insider Sale and Revenue Guidance Cut

Font: Financial Modeling Prep  • Sep 03, 2026

• BetterHelp President Fernando M. Rodrigues sold 9,812 shares of Teladoc Health common stock for $6.51 per share, totaling $63,876.00.
• The BetterHelp segment experienced significant challenges, with revenues declining by 11.6% and adjusted EBITDA margin falling to 0.2% in Q2 2026.
• Teladoc Health (NYSE:TDOC) lowered its full-year 2026 revenue guidance, leading to a potential securities fraud investigation by Pomerantz LLP.

Teladoc Health (NYSE:TDOC) is a leading virtual healthcare company with a market capitalization of approximately $1.1 billion. The company provides a range of telehealth services, from general medical care to mental health support through its BetterHelp platform. Teladoc Health operates in a highly competitive virtual-care market, which can affect its ability to grow and set prices.

On September 3, 2026, an insider transaction occurred involving the President of BetterHelp, Fernando M. Rodrigues. He sold 9,812 shares of Teladoc Health common stock at a price of $6.51 per share. The total value of this sale was approximately $63,876.00. Following this transaction, Rodrigues no longer owns any shares in the company.

This sale comes as the BetterHelp segment faces significant challenges. In the second quarter of 2026, BetterHelp's revenues declined by 11.6%. Its adjusted EBITDA margin, a measure of operational profitability, also fell sharply to just 0.2%. This is partly due to a faster-than-expected shift from customers paying with cash to using insurance.

The company-wide outlook has also been adjusted. Teladoc Health lowered its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, down from a previous forecast of $2.48 billion to $2.58 billion. Following this, as highlighted by PR Newswire, Pomerantz LLP began an investigation into claims of potential securities fraud.

Despite these issues, some financial metrics suggest the stock may be undervalued. As detailed in the Zacks Equity Research Analyst Blog, Teladoc Health has a forward Price-to-Sales ratio of 0.47x. This ratio, which compares the company's stock price to its expected revenues, is below the industry average of 0.53x, suggesting it is trading at a discount.